The company is commercializing the test, after completing the requisite ‘Fit-for-Purpose’ assay validation conducted at Icon Central Laboratories.

Amarantus BioScience president and CEO Gerald Commissiong said: "We have built significant value in our LymPro program over the past two years, and the initiation of our launch to the pharmaceutical industry represents a critical milestone for Amarantus.

"We believe LymPro is poised to establish a market leading position as the first fundamental disease-biology based, blood biomarker test for Alzheimer’s disease in the world, an area with significant unmet need and for which there has recently been a great deal of interest in the mainstream media."

The LymPro is a diagnostic blood test, which determines the ability of peripheral blood lymphocytes (PBLs) to withstand an external mitogenic stimulation that induces them to enter the cell cycle.

LymPro is said to be unique in the use of PBLs as a surrogate for neuronal cell function, advising a common immune-based relationship between PBLs and neurons in the brain.